WKN: | 900964 |
ISIN: | US64125C1099 |
Land: | USA |
Branche: | Chemie, Pharma, Bio- & Medizintechnik |
Sektor: | Biotechnologie |
Weshalb die Neurocrine Biosciences-Aktie
ein B-Rating hat,
erfahren Sie im Performance-Check
vom 25. Juli 2025 Info.
Rang | Datum | Vorjahr | Schluss | Performance |
---|---|---|---|---|
1 | 2010 | 2,00 | 5,82 | 191,00% |
2 | 2015 | 18,28 | 50,68 | 177,24% |
3 | 2014 | 6,74 | 18,28 | 171,22% |
4 | 2017 | 35,87 | 62,87 | 75,27% |
5 | 2019 | 60,91 | 98,22 | 61,25% |
6 | 2001 | 38,00 | 59,50 | 56,58% |
7 | 2022 | 73,88 | 111,94 | 51,52% |
8 | 2005 | 36,00 | 52,75 | 46,53% |
9 | 2013 | 5,60 | 6,74 | 20,36% |
10 | 2011 | 5,82 | 6,58 | 13,06% |
11 | 2024 | 118,85 | 132,80 | 11,74% |
12 | 2023 | 111,94 | 118,85 | 6,17% |
13 | 2003 | 45,00 | 43,84 | -2,58% |
14 | 2021 | 75,86 | 73,88 | -2,61% |
15 | 2018 | 62,87 | 60,91 | -3,12% |
16 | 2012 | 6,58 | 5,60 | -14,89% |
17 | 2025 | 132,80 | 112,75 | -15,10% |
18 | 2009 | 2,40 | 2,00 | -16,67% |
19 | 2004 | 43,84 | 36,00 | -17,88% |
20 | 2008 | 3,00 | 2,40 | -20,00% |
Rang | Datum | Vorjahr | Schluss | Performance |
---|---|---|---|---|
1 | 2006 | 52,75 | 7,84 | -85,14% |
2 | 2007 | 7,84 | 3,00 | -61,73% |
3 | 2016 | 50,68 | 35,87 | -29,22% |
4 | 2002 | 59,50 | 45,00 | -24,37% |
5 | 2020 | 98,22 | 75,86 | -22,77% |
6 | 2008 | 3,00 | 2,40 | -20,00% |
7 | 2004 | 43,84 | 36,00 | -17,88% |
8 | 2009 | 2,40 | 2,00 | -16,67% |
9 | 2025 | 132,80 | 112,75 | -15,10% |
10 | 2012 | 6,58 | 5,60 | -14,89% |
11 | 2018 | 62,87 | 60,91 | -3,12% |
12 | 2021 | 75,86 | 73,88 | -2,61% |
13 | 2003 | 45,00 | 43,84 | -2,58% |
14 | 2023 | 111,94 | 118,85 | 6,17% |
15 | 2024 | 118,85 | 132,80 | 11,74% |
16 | 2011 | 5,82 | 6,58 | 13,06% |
17 | 2013 | 5,60 | 6,74 | 20,36% |
18 | 2005 | 36,00 | 52,75 | 46,53% |
19 | 2022 | 73,88 | 111,94 | 51,52% |
20 | 2001 | 38,00 | 59,50 | 56,58% |